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Introduction {#jdi12614-sec-0005}
============

Type 2 diabetes is a complex metabolic disorder characterized by chronic hyperglycemia, the prevalence of which is estimated to rise from 171 million in 2000 to 366 million in 2030 worldwide[1](#jdi12614-bib-0001){ref-type="ref"}, [2](#jdi12614-bib-0002){ref-type="ref"}, [3](#jdi12614-bib-0003){ref-type="ref"}. There are various factors contributing to the growth of diabetic incidence, and daily diet stands out as an important factor[4](#jdi12614-bib-0004){ref-type="ref"}, [5](#jdi12614-bib-0005){ref-type="ref"}.

Since the year 1966, it has been reported that the incidence of type 2 diabetes has been significantly reduced with high fish and seafood consumption[6](#jdi12614-bib-0006){ref-type="ref"}, [7](#jdi12614-bib-0007){ref-type="ref"}, [8](#jdi12614-bib-0008){ref-type="ref"} in northwestern Greenland, which might be attributed to the effect of omega‐3 fatty acids, the predominant fatty acid composition of seafood. In the past decades, notwithstanding plenty of reports that have been published about the effects of omega‐3 fatty acids on diabetes prevention, discrepancies still remain. Several cohort studies showed that high intake of omega‐3 fatty acids related to a lower prevalence of type 2 diabetes[5](#jdi12614-bib-0005){ref-type="ref"}, [9](#jdi12614-bib-0009){ref-type="ref"}, [10](#jdi12614-bib-0010){ref-type="ref"}, [11](#jdi12614-bib-0011){ref-type="ref"}; whereas some other studies showed positive[12](#jdi12614-bib-0012){ref-type="ref"}, [13](#jdi12614-bib-0013){ref-type="ref"} or null associations[14](#jdi12614-bib-0014){ref-type="ref"}, [15](#jdi12614-bib-0015){ref-type="ref"}. Inconsistent results were also reported in clinical trials that investigated the effect of fish oil supplementation on glucose homeostasis[16](#jdi12614-bib-0016){ref-type="ref"}, [17](#jdi12614-bib-0017){ref-type="ref"}, [18](#jdi12614-bib-0018){ref-type="ref"}, [19](#jdi12614-bib-0019){ref-type="ref"}, [20](#jdi12614-bib-0020){ref-type="ref"}.

Recent published systematic reviews reported that omega‐3 fatty acids supplementation was either positively or insignificantly associated with type 2 diabetes development[21](#jdi12614-bib-0021){ref-type="ref"}, [22](#jdi12614-bib-0022){ref-type="ref"}, [23](#jdi12614-bib-0023){ref-type="ref"}, [24](#jdi12614-bib-0024){ref-type="ref"}, [25](#jdi12614-bib-0025){ref-type="ref"}. These conclusions suggest an unfavorable effect of omega‐3 supplementation on people who are prone to develop to diabetes; for example, people with obesity, insulin resistance and hyperlipidemia. However, some other systematic reviews reported that omega‐3 has beneficial effects on metabolic‐related diseases; it exerts a cardioprotective effect, reduces ischemic stroke risk, corrects high triglycerides level and increases insulin sensitivity[21](#jdi12614-bib-0021){ref-type="ref"}, [26](#jdi12614-bib-0026){ref-type="ref"}. These contradicting notions might confound physicians and nutritionists on dietary guidance. Additionally, these meta‐analysis papers failed to dissect the source that results in this contradiction. We therefore carried out a meta‐analysis with a dose--response model and subgroup analysis in prospective cohort studies to evaluate the potential factors that influence the effect of omega‐3 fatty acids consumption on type 2 diabetes incidence.

Methods {#jdi12614-sec-0006}
=======

Data sources and searches {#jdi12614-sec-0007}
-------------------------

A comprehensive literature search was carried out of the Pubmed, Cochrane Library, Medline, SIGLE and EMBASE databases, and National Research Register with the last date of inclusion to be the end of May 2016. The Medical Subject Heading terms and keywords for database searching included (i) omega‐3 or n‐3 or ω‐3 fatty acids; (ii) docosapentaenoic acid or DPA; (iii) eicosapentaenoic acid or EPA; (iv) docosahexaenoic acid or DHA; and (v) fish oil(s). We combined these terms with diabetes mellitus, type 2 diabetes or T2D, which was described in detail in our previous work[26](#jdi12614-bib-0026){ref-type="ref"}. Cross‐references of studies or reviews were also examined manually.

Two investigators (Shao and Chen) worked independently to determine the eligible studies by reviewing the titles, abstracts and keywords. The manuscripts were obtained in full‐text version for further assessment if the study: (i) was a cohort design investigating the association between omega‐3 supplementation and the incidence of type 2 diabetes; (ii) analyzed relative risk (RR), hazard ratios (HR) or odds ratios (OR) with 95% confidence interval (CI); (iii) reported at least three quantitative exposure levels of omega‐3 for dose--response analysis; (iv) showed the method of dietary assessment; and (v) included the participants at baseline who were not diagnosed as type 2 diabetes.

Data extraction {#jdi12614-sec-0008}
---------------

Data extraction was independently carried out by Shao and Chen. The extracted information included composition and intake amounts of omega‐3, number of cases and person‐years of follow up in each exposure category, follow‐up years, study setting, diabetes diagnosis, baseline characteristics of included participants (number of participants, age at recruitment, sex and ethnicity), and the adjusted RR with 95% CI. For studies with OR or HR data, we converted OR and HR into RR using a previously published formula[27](#jdi12614-bib-0027){ref-type="ref"}. The corresponding CI values were also converted. When studies reported results with different models for variable adjustment, data were extracted from models including the most potential confounders.

Quality assessment {#jdi12614-sec-0009}
------------------

Quality assessment of cohort studies was carried out based on the Newcastle--Ottawa Scale Criteria[28](#jdi12614-bib-0028){ref-type="ref"}, which were performed by Shao and Chen independently with discrepancies resolved by Yang. The maximum score that can be assigned by the Newcastle--Ottawa Scale is 9 points in three broad items: (i) selection of study groups (up to 4 points); (ii) comparability of groups (up to 2 points); and (iii) assessment of exposure and outcomes (up to 3 points). The overall evaluation of included trials is presented in Table [S1](#jdi12614-sup-0002){ref-type="supplementary-material"}.

Statistical analysis {#jdi12614-sec-0010}
--------------------

The meta‐analysis was carried out using [stata]{.smallcaps} 11.0 (StataCorp, College Station, TX, USA). Extracted data from cohort studies were analyzed with a fixed effects model to calculate the pooled RR comparing the highest versus the lowest intake of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) or mixed omega‐3 with 95% CI. *P* \< 0.05 was considered to be statistically significant. Heterogeneity was assessed using the χ^2^ method[29](#jdi12614-bib-0029){ref-type="ref"}. A random effects model was used when heterogeneity was statistically significant (*P* \< 0.1)[30](#jdi12614-bib-0030){ref-type="ref"}.

The methods proposed by Greenland and Orsini[31](#jdi12614-bib-0031){ref-type="ref"}, [32](#jdi12614-bib-0032){ref-type="ref"} were used in our dose--response analysis. To assess the possible non‐linear trends between ω‐3 fatty acid intake and type 2 diabetes risk, we used a restricted cubic spline model, in which four fixed knots at the 5th, 35th, 65th and 95th percentile of the exposure distribution were set up[33](#jdi12614-bib-0033){ref-type="ref"}, [34](#jdi12614-bib-0034){ref-type="ref"}. The regression coefficients of the second and third splines were assumed equal to zero to test the non‐linearity using the Wald test[31](#jdi12614-bib-0031){ref-type="ref"}. Linear analysis was chosen in the subsequent calculating steps if *P* ≥ 0.05; otherwise, a non‐linear model was used.

The generalized least‐square model was used to estimate the RR of type 2 diabetes for daily dose increment of ω‐3 fatty acid consumption; and a random‐effects model was applied to synthesize the study‐specific regression coefficients[35](#jdi12614-bib-0035){ref-type="ref"}, [36](#jdi12614-bib-0036){ref-type="ref"}. The mean or median value of each exposure level was allocated to the corresponding RR[36](#jdi12614-bib-0036){ref-type="ref"}. The lowest exposure category was defined as a referent; whereas other categories were centralized to the referent dose. Incomplete data was calculated using an improved method of Bekkering *et al* [37](#jdi12614-bib-0037){ref-type="ref"}.

Subgroup analysis was carried out according to: (i) duration of studies (\<16 years vs ≥16 years); (ii) ethnicity (Asian vs USA/European); (iii) age at the initial stage of studies (\<54 years vs ≥54 years).

The potential source of heterogeneity between included studies was investigated through meta‐regression analysis with a *P*‐value \<0.1 as statistical significance. The items including type of omega‐3 fatty acids, study duration, ethnicity and age at recruitment were analyzed in the regression model. A funnel plot with Egger\'s linear regression analysis was used to determine the risk of publication bias by assessing the asymmetry of the funnel plot. A *P*‐value \<0.1 was considered to be of significant bias[38](#jdi12614-bib-0038){ref-type="ref"}, [39](#jdi12614-bib-0039){ref-type="ref"}.

Results {#jdi12614-sec-0011}
=======

Description of studies {#jdi12614-sec-0012}
----------------------

The initial search obtained 1,450 publications in 2016, of which 30 studies were investigated in full‐text articles (Figure [S1](#jdi12614-sup-0001){ref-type="supplementary-material"}). Finally, five articles with 10 cohort trials were potentially eligible[5](#jdi12614-bib-0005){ref-type="ref"}, [9](#jdi12614-bib-0009){ref-type="ref"}, [10](#jdi12614-bib-0010){ref-type="ref"}, [12](#jdi12614-bib-0012){ref-type="ref"}, [13](#jdi12614-bib-0013){ref-type="ref"}.

The scores of included studies, according to the Newcastle--Ottawa Scale Criteria, ranged from 5 to 8 (Table [S1](#jdi12614-sup-0002){ref-type="supplementary-material"}). A total of 426,852 participants were included. The individual sample size varied from 35,988 to 91,669 participants, and the follow‐up duration was 4.1--18 years. These participants were non‐diabetic at the beginning of each study, and were aged from 26 to 78 years. The Validated Food Frequency Questionnaire was used to assess the dietary method. EPA, DHA and mixed omega‐3 fatty acids were examined as dietary factors, the amounts of which were organized in five quintiles. The pooled RR for type 2 diabetes was calculated by comparing the RR corresponding to the highest exposure category of omega‐3 with that of the lowest one.

Omega‐3 fatty acids intake and risk of Type 2 diabetes {#jdi12614-sec-0013}
------------------------------------------------------

A total of 10 cohort studies with three dietary factors (EPA, DHA and mixed omega‐3) were included in the present meta‐analysis. As shown in Figure [1](#jdi12614-fig-0001){ref-type="fig"}, the overall effect of total omega‐3 fatty acids on the risk of type 2 diabetes was insignificant (RR = 1.14, 95% CI 0.99--1.31, *P* = 0.062). Furthermore, we analyzed the association of mixed omega‐3 fatty acids supplementation with type 2 diabetes, which was found to be insignificant (RR = 1.07, 95% CI 0.92--1.25, *P* = 0.35) as well. Interestingly, despite the limited included studies, the consumption of single omega‐3 subtype (either EPA or DHA) was related to an increased risk of type 2 diabetes (Figure [1](#jdi12614-fig-0001){ref-type="fig"}) with the pooled effect size being 1.45 (95% CI 1.31--1.60, *P* \< 0.001).

![Forest plot of meta‐analysis for type 2 diabetes risk and omega‐3 fatty acids supplementation. CI, confidence interval; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; HPFS, Health Care Professionals Study; IWHS, Iowa Women\'s Health Study; NHS, Nurses\' Health Study; NHS2, Nurses\' Health Study II;RR, relative risk; SCHS, Singapore Chinese Health Study; SMHS, Shanghai Men\'s Health Study; SWHS, Shanghai Women\'s Health Study; WHS3, Women\'s Health Study.](JDI-8-480-g001){#jdi12614-fig-0001}

Dose--response analysis {#jdi12614-sec-0014}
-----------------------

Among the 10 included studies, a significant non‐linear association was identified (*P* \< 0.001 for non‐linear test). The dose--response curve showed an inverted U‐shape with 0.43 g/day as the peak point. Specifically, within people consuming 0.10--0.43 g n‐3 fatty acids per day, an increment dose of fatty acids intake was generally associated with a significant higher type 2 diabetes risk as compared with the referent dosage (0 g/day). However, supplementation of n‐3 fatty acids with 0.43--0.75 g/day showed a decreased tendency in the type 2 diabetes risk as compared with the 0.10--0.43 g/day dose range. RR in the \>0.75 g/day category (0.75--1.08 g/day) was further decreased with no statistical significance (Figure [2](#jdi12614-fig-0002){ref-type="fig"}a).

![Non‐linear dose--response relationship between omega‐3 fatty acids consumption and type 2 diabetes (T2D) risk based on (a) total omega‐3, (b) single omega‐3 and (c) mixed omega‐3.](JDI-8-480-g002){#jdi12614-fig-0002}

Two studies investigated the association of type 2 diabetes risk and single omega‐3 fatty acids intake. In accordance with results we obtained in Figure [1](#jdi12614-fig-0001){ref-type="fig"}, a significant positive association between EPA/DHA with type 2 diabetes risk was observed in the non‐linear model (Figure [2](#jdi12614-fig-0002){ref-type="fig"}b). To exclude the possible interference of single n‐3 fatty acids, we carried out a non‐linear analysis in eight studies with mixed omega‐3 as the dietary factor (Figure [2](#jdi12614-fig-0002){ref-type="fig"}c) and a similar curve was obtained with that in Figure [2](#jdi12614-fig-0002){ref-type="fig"}a (*P* \< 0.001 for non‐linear test, *P* \< 0.001 for overall association).

Subgroup analysis and heterogeneity evaluation {#jdi12614-sec-0015}
----------------------------------------------

A high degree of heterogeneity was observed in the overall analysis (*I* ^2^ = 89.8%, *P* \< 0.001). Thus, we carried out further subanalysis according to ethnicity, study duration and age of participants at recruitment to explore the source of heterogeneity. As shown in Figure [3](#jdi12614-fig-0003){ref-type="fig"}a, studies based on Asian populations showed a protective effect of omega‐3 fatty acids intake against the development of type 2 diabetes (pooled RR = 0.82, *P* \< 0.001). Conversely, studies on Western populations showed increased risk of type 2 diabetes (pooled RR = 1.30, *P* \< 0.001).

![Forest plot of meta‐analysis for type 2 diabetes risk and omega‐3 fatty acids supplementation according to (a) Asian/Western populations, (b) duration of follow up and (c) age of participants at baseline. CI, confidence interval; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; HPFS, Health Care Professionals Study; IWHS, Iowa Women\'s Health Study; NHS, Nurses\' Health Study; NHS2, Nurses\' Health Study II;RR, relative risk; SCHS, Singapore Chinese Health Study; SMHS, Shanghai Men\'s Health Study; SWHS, Shanghai Women\'s Health Study; WHS3, Women\'s Health Study.](JDI-8-480-g003){#jdi12614-fig-0003}

We chose the median values as the cut‐off points of study duration (16 years) and participants\' age (54 years). There was no significant association between omega‐3 fatty acids intake and type 2 diabetes incidence in studies with \<16 years of follow up (pooled RR = 0.97, *P* = 0.782); whereas studies with more than 16 years of follow up (including 16 years) showed an increased risk of type 2 diabetes (pooled RR = 1.33, *P* \< 0.001; Figure [3](#jdi12614-fig-0003){ref-type="fig"}b). In subgroup analysis according to age at recruitment (Figure [3](#jdi12614-fig-0003){ref-type="fig"}c), individuals who were recruited at the age of \>54 years presented increased risk of type 2 diabetes (pooled RR = 1.24, *P* = 0.04). No significant association was observed in a subgroup that included individuals with initial age \<54 years (pooled RR = 1.05, *P* = 0.574).

According to the aforementioned data, a high degree of heterogeneity was still observed in all subgroup analyses, except in studies with Asian participants. Subsequently, we carried out a meta‐regression analysis according to the following covariates: ethnicity, age of participants at baseline, omega‐3 composition and follow‐up duration (Table [S2](#jdi12614-sup-0003){ref-type="supplementary-material"}). Univariate analysis showed that no significant association was observed in the covariate of age (*P* = 0.783); whereas ethnicity (*P* \< 0.01), omega‐3 composition (*P* = 0.10) and study duration (*P* = 0.01) were possible factors that caused the heterogeneity. Thus, we selected these factors for multivariate analysis, and identified ethnicity (*P* = 0.007) and omega‐3 composition (*P* = 0.064) as the major factors that contribute to the heterogeneity between studies involved (Table [1](#jdi12614-tbl-0001){ref-type="table-wrap"}).

###### 

Results of source meta‐regression analysis to explore heterogeneity (multivariate analysis)

  Covariates            Exp (b)   SE     *P*
  --------------------- --------- ------ ------
  Ethnicity             0.63      0.07   0.01
  Omega‐3 composition   0.86      0.06   0.06
  Follow‐up duration    0.99      0.01   0.65

The dependent variable is the ln(relative risk) (lnRR) for type 2 diabetes incidence from each study. Weights were assigned according to the estimated variance of lnRR. exp (b), relative risk of estimates; RR, relative risk; SE, standard error of relative risk of estimates.

John Wiley & Sons, Ltd

Furthermore, we carried out subgroup analysis in USA/European populations according to omega‐3 composition. As shown in Figure [4](#jdi12614-fig-0004){ref-type="fig"}, no significant heterogeneity was observed in the single (*I* ^2^ = 0.0%, *P* = 0.328) or mixed (*I* ^2^ = 42.1%, *P* = 0.141) omega‐3 subgroups, which further confirmed the source of heterogeneity identified in the present study.

![Forest plot of meta‐analysis for type 2 diabetes risk and omega‐3 fatty acids supplementation based on omega‐3 composition in USA/European population. CI, confidence interval; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; HPFS, Health Care Professionals Study; IWHS, Iowa Women\'s Health Study; NHS, Nurses\' Health Study; NHS2, Nurses\' Health Study II;RR, relative risk; WHS3, Women\'s Health Study.](JDI-8-480-g004){#jdi12614-fig-0004}

Publication bias evaluation {#jdi12614-sec-0016}
---------------------------

As shown in Figure [5](#jdi12614-fig-0005){ref-type="fig"}, the risk of publication bias was evaluated using the method of funnel plot with Egger\'s linear regression line. Although the graph of the funnel plot showed an asymmetrical shape, no publication bias was observed in Egger\'s test (*P* = 0.411).

![Funnel plot with Egger\'s regression line for risk ratio of type 2 diabetes (T2D). lnRR, ln(relative risk).](JDI-8-480-g005){#jdi12614-fig-0005}

Discussion {#jdi12614-sec-0017}
==========

This meta‐analysis pooled 10 cohort studies with 426,852 participants to explore the association between omega‐3 consumption and type 2 diabetes risk. It is known that omega‐3 fatty acids include EPA, docosapentaenoic acid (DPA), DHA, α‐linolenic acid and so on[40](#jdi12614-bib-0040){ref-type="ref"}. Dietary factors included in these cohort studies were EPA, DHA and mixed omega‐3. Although the overall effect of total omega‐3 fatty acids was insignificant on type 2 diabetes development, the supplementation of a single omega‐3 subtype was correlated to an increased risk of type 2 diabetes. The dose--response analysis presented an inverted U‐shaped curve of type 2 diabetes risk, with the peak point at 0.43 g/days of omega‐3 supplementation. Subgroup analysis identified that omega‐3 consumption only showed beneficial effects in Asian subjects.

It was identified that individuals with single omega‐3 supplementation presented a more obvious trend on type 2 diabetes progression when compared with mixed omega‐3 intake. Although the included trials were limited, this finding still impelled us to assume whether synergic action *in vivo* of different omega‐3 individuals could alleviate the detrimental effects of single omega‐3 subtype intake on type 2 diabetes development. Mixed omega‐3 fatty acids used in the Women\'s Health Study included EPA, DHA and DPA[12](#jdi12614-bib-0012){ref-type="ref"}. In the Shanghai Women\'s Health Study, participants were supplemented with omega‐3 mixtures of EPA and DHA[5](#jdi12614-bib-0005){ref-type="ref"}. The composition of omega‐3 fatty acids in the Singapore Chinese Health Study was EPA, DHA and α‐linolenic acid[9](#jdi12614-bib-0009){ref-type="ref"}. However, in the Nurses\' Health Study, Nurses\' Health Study II, Health Care Professionals Study, Shanghai Men\'s Health Study and Iowa Women\'s Health Study, detailed information of mixed omega‐3 was unavailable[10](#jdi12614-bib-0010){ref-type="ref"}, [13](#jdi12614-bib-0013){ref-type="ref"}. Additionally, the percentage of the individual fatty acid in mixed omega‐3 supplementation is not clear. Our previous study found that a high ratio of EPA/DHA could improve insulin resistance[26](#jdi12614-bib-0026){ref-type="ref"}. It is known that insulin resistance is the major pathophysiological feature of type 2 diabetes[27](#jdi12614-bib-0027){ref-type="ref"}. Therefore, we assumed that the varied compositions and proportions of omega‐3 subtypes might explain, at least in part, the divergences of their effects on type 2 diabetes prevention and development. Our heterogeneity analysis also identified that the composition of omega‐3 contributed a great deal to the high degree of heterogeneity between involved trails. More investigations focusing on this assumption remain to be carried out, which might bring a new concept to omega‐3 supplementation.

According to the inverted U‐shaped dose--response curve with \~1 g/day dose range (Figure [2](#jdi12614-fig-0002){ref-type="fig"}), we presume that daily intake of approximately 0.43 g omega‐3 fatty acids might impose the most significant detrimental effect on type 2 diabetes development. Either a lower or higher supplementation dose showed a decreasing tendency. In contrast, several studies with a higher dose of omega‐3 fatty acids intake have shown beneficial effects on some diseases that share similar pathological processes and/or risk factors with type 2 diabetes, such as hyperlipidemia[41](#jdi12614-bib-0041){ref-type="ref"}, insulin sensitivity[42](#jdi12614-bib-0042){ref-type="ref"}, [43](#jdi12614-bib-0043){ref-type="ref"}, [44](#jdi12614-bib-0044){ref-type="ref"}, obesity[45](#jdi12614-bib-0045){ref-type="ref"}, [46](#jdi12614-bib-0046){ref-type="ref"}, non‐alcoholic fatty liver disease[47](#jdi12614-bib-0047){ref-type="ref"}, inflammatory reaction[48](#jdi12614-bib-0048){ref-type="ref"} and cardiovascular diseases[49](#jdi12614-bib-0049){ref-type="ref"}. Pirillo *et al*.[41](#jdi12614-bib-0041){ref-type="ref"} suggested that the optimal dosage should be 3--4 g/day to achieve a significant lipid‐lowering effect. Daily consumption of 0.85--1.8 g/day omega‐3 was advised to provide a protective efficacy in people with documented cardiovascular disease[50](#jdi12614-bib-0050){ref-type="ref"}, [51](#jdi12614-bib-0051){ref-type="ref"}. Additionally, 0.7--5.1 g/day of n‐3 fatty acids supplementation was associated with a greater reduction on urine protein excretion[52](#jdi12614-bib-0052){ref-type="ref"}. These findings together with the dose--response curve in the present study led us to the concept that higher omega‐3 intake amount (more than 0.43 g/day at least) might provide a protective effect, or at least a risk‐lowering tendency in type 2 diabetes. An appropriate dose range to achieve a beneficial effect on type 2 diabetes is awaiting identification.

Furthermore, our subgroup analysis showed that omega‐3 fatty acids exerted beneficial effects in Asian populations, but were detrimental in Western populations. However, there were just two studies that included Asian populations (Chinese people in particular). More investigations across different Asian groups were required. Nevertheless, the distinct lifestyle between these two populations, especially the cooking style, might result in the contrary observations. It is speculated that cooking style (e.g., fried in Asian style or raw in Western style) can influence the generation of omega‐3 derived lipid mediators and resultantly change the physiological effects of omega‐3 fatty acids *in vivo*. Additionally, Eastern and Western populations share totally different dietary patterns. It would be significant to identify the biochemical interactions between omega‐3 fatty acids and other multifarious dietary factors. Furthermore, fish oil‐related gene polymorphisms in different ethnicities could also contribute to the opposite effects observed in USA/European and Asian populations. A recent study reported that carriers of ELOVL2 single nucleotide polymorphism minor alleles with a daily intake of 1.8 g omega‐3 showed a more obvious increase of plasma EPA and DHA when compared with non‐carriers. Thus, these carriers might benefit from high levels of plasma omega‐3[53](#jdi12614-bib-0053){ref-type="ref"}. It is known that adiponectin has a beneficial effect on the improvement of insulin sensitization[54](#jdi12614-bib-0054){ref-type="ref"}. Alsaleh *et al*.[55](#jdi12614-bib-0055){ref-type="ref"} reported that the ADIPOQ gene polymorphism interacted with fish oil to affect plasma adiponectin levels. More studies that assess the relationship between omega‐3 fatty acids and single nucleotide polymorphisms in different ethnicities might shed light on the complicated effects of omega‐3 on different ethnicities.

Subanalysis according to follow‐up duration recognized that studies with \>16 years of follow up showed a positive effect of omega‐3 intake on type 2 diabetes development; whereas insignificant findings were identified in studies with \<16 years of follow up. Due to aging as one of the primary risk factors for type 2 diabetes[56](#jdi12614-bib-0056){ref-type="ref"}, [57](#jdi12614-bib-0057){ref-type="ref"}, there should be no question on this conclusion, as longer follow‐up duration implies more aged participants. The results from subanalyses by age with a cut‐off point of 54 years obtained consistent results. These data show that early supplementation of omega‐3 fatty acids might achieve a beneficial outcome for type 2 diabetes prevention.

Furthermore, we evaluated the risk of publication bias with the method of funnel plot. Although there was some suggestion of asymmetry from visual inspection, no statistical significance was identified. Thus, it is assumed that such asymmetrical shape should not be a marked factor that affects our conclusions. An asymmetrical funnel plot usually indicates a possible publication bias; nevertheless, there are other factors that can cause the asymmetry of a funnel plot, such as the involvement of small‐size studies and marked heterogeneity between included studies[58](#jdi12614-bib-0058){ref-type="ref"}. As shown in Figure [5](#jdi12614-fig-0005){ref-type="fig"}, dots in the funnel plot, which represent included studies, are spread widely, suggesting large heterogeneity between these studies. Thus, it is estimated that the asymmetry of the funnel plot might result from the study heterogeneity, but not publication bias.

In the present study, a high degree of heterogeneity can be observed either in overall or in subgroup analysis, which might overestimate or underestimate the effect of omega‐3 fatty acids on type 2 diabetes risk. Such heterogeneity could be attributed to several limitations of the included studies. First, the included studies contained people from different ethnicities. Just three trials showed the protective effect of omega‐3 fatty acids on type 2 diabetes, all of which chose Asian populations as recruited participants. Second, various dietary factors (single or mixed omega‐3) were used in these studies; however, the detailed information about the composition and percentage of supplemented omega‐3 was not available. Third, the included studies ranged from 1990 to 2011; hence, the progression of techniques and the update of testing devices might affect the obtained data. Thus, we carried out meta‐regression analysis to trace the source of heterogeneity. Ethnicity and omega‐3 composition were identified as the major factors.

In conclusion, the present data are relevant to clinicians and nutritionists adopting optimized dietary guidance for diabetes‐prone populations. We assumed that dietary supplementation with different subtypes of omega‐3 results in varied effects on type 2 diabetes prevention. However, the present study did not provide evidence to discourage the use of omega‐3 fatty acids, because the analyzed studies have shown the decreased incidence of type 2 diabetes with mixed omega‐3 supplementation in Asian populations. The appropriate dosage and compositions of omega‐3, the optimized cooking method, and early omega‐3 supplementation might be beneficial for type 2 diabetes prevention.
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